Atrioventricular Septal Defect (AVSD) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

Atrioventricular Septal Defect (AVSD) Market Outlook

Thelansis’s “Atrioventricular Septal Defect (AVSD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Atrioventricular Septal Defect (AVSD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Atrioventricular Septal Defect (AVSD) Overview

Atrioventricular septal defects (AVSD) are congenital heart conditions marked by varying degrees of atrial and ventricular septal defects and a shared or partially separated atrioventricular orifice. A partial AVSD involves specific features like an atrial septal defect, separate atrioventricular valves with a common junction, a ventricular septal defect, and a cleft mitral valve. On the other hand, a complete AVSD features a common atrioventricular valve with an atrial septal defect and an unrestricted inlet-type ventricular septal defect. The clinical presentation of AVSD depends on the type of defect, the size of the intracardiac shunt, and any accompanying heart malformations. Complete AVSD patients often show signs of pulmonary congestion and right heart failure early in life due to a substantial left-to-right shunt, significantly as pulmonary vascular resistance decreases after birth. Heart failure and Eisenmenger syndrome might develop earlier in cases with atrioventricular valve regurgitation, ventricular imbalance, or aortic coarctation. Patients with partial AVSD, without complex congenital heart issues and minimal valve regurgitation, usually remain asymptomatic in early childhood and are typically diagnosed incidentally based on findings like heart murmurs and fixed splitting due to an atrial septal defect. The prognosis for untreated AVSD is bleak, with roughly 50% of patients not surviving infancy due to heart failure or pulmonary infections. Those who survive beyond the first year often develop irreversible pulmonary vascular disease and eventually, experience a reversal of the shunt. Patients who undergo surgical repair have a 90% survival rate for around 15 years, although approximately 9% to 10% of them may require reoperation within that period. Most complications related to AVSD are linked to intracardiac shunting and atrioventricular valve regurgitation. Complete AVSD leads to right-sided heart overload, heart failure, and pulmonary congestion at a young age, contributing to a significant infant mortality rate. This shunt can lead to irreversible pulmonary vascular disease, pulmonary hypertension, and Eisenmenger syndrome without correction.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Atrioventricular Septal Defect (AVSD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034